European Respiratory Society Annual Congress 2013

Abstract Number: 958

Publication Number: 1800

Abstract Group: 1.1. Clinical Problems

Keyword 1: Neoplastic diseases Keyword 2: Acute respiratory failure Keyword 3: No keyword

Title: Pulmonary tumor thrombotic microangiopathy: A clinical analysis of 30 autopsy cases

Dr. Hironori 6483 Uruga uruga.hironori@gmail.com MD ¹, Dr. Takeshi 6484 Fujii tkshfj@gmail.com MD ², Dr. Atsuko 6485 Kurosaki atsuko-k@ya2.so-net.ne.jp MD ³, Dr. Yui 6486 Takahashi takahashiyui413@gmail.com MD ¹, Dr. Kazumasa 6487 Ogawa kazpy@u01.gate01.com MD ¹, Dr. Masayuki 6488 Ishibashi ishibashiishibashi2000@yahoo.co.jp MD ¹, Dr. Toshitaka 6489 Sato redrum7272000@gmail.com MD ¹, Dr. Sayaka 6490 Mochiduki sayakam0920@gmail.com MD ¹, Dr. Shigeo 6491 Hanada gourouhanada@yahoo.co.jp MD ¹, Dr. Shinko 6492 Suzuki suzukisnow@gmail.com MD ¹, Dr. Hisashi 6493 Takaya hisashi5240@yahoo.co.jp MD ¹, Dr. Atsushi 6494 Miyamoto atsushimotty@gmail.com MD ¹, Dr. Nasa 6495 Morokawa nasa@qb3.so-net.ne.jp MD ¹, Dr. Sakae 6496 Homma sahomma@med.toho-u.ac.jp MD ⁴ and Dr. Kazuma 6497 Kishi kazumak@toranomon.gr.jp MD ¹. ¹ Departments of Respiratory Medicine, Respiratory Center, Toranomon Hospital, Tokyo, Japan ; ² Department of Pathology, Toranomon Hospital, Tokyo, Japan ; ³ Department of Diagnostic Radiology, Fukujyuji Hospital, Tokyo, Japan and ⁴ Department of Respiratory Medicine, Toho University Omori Medical Center, Tokyo, Japan .

Body: Objective: Pulmonary tumor thrombotic microangiopathy (PTTM) is a rare, fatal form of pulmonary arterial tumor embolism. The aim of this study was to evaluate the clinical characteristics along the pathological and immunohistochemical findings of PTTM. Methods: Autopsy records in our hospital from 1983 to 2008 were reviewed, and those of patients who died from pulmonary tumor embolism resulting from malignant neoplasm were retrieved. The relevant tissue slides were reevaluated to confirm the diagnosis and examined immunohistochemically. Results: Among 2215 consecutive autopsy cases with carcinomas, 30 patients (1.4%) were diagnosed with definitive PTTM. The common symptom was progressive dyspnea. A hypercoagulative state was observed in all measured cases (n = 21). Chest computed tomography findings (n = 6) included consolidations, ground-glass opacities, small nodules, and tree-in-bud appearance. Perfusion scans was performed in 7 patients, 6 of whom demonstrated multiple small defects. The median survival time after initiation of oxygen supplementation was 9 days. The most frequent primary site was the stomach (n = 18; 60%), and the most frequent histological type was adenocarcinoma (28/30; 93.3%). Immunohistochemical findings for tumor cells located within the tumor emboli were positive for vascular endothelial growth factor (28/29; 96.6%) and tissue factor (29/29; 100%). Conclusions: We should suspect PTTM in cancer patients with acute worsening respiratory insufficiency accompanying elevated coagulation factors without embolism in major pulmonary arteries. The PTTM patients in our study had poor prognoses. Vascular endothelial growth factor and tissue factor may play important roles in PTTM.